Annual Revenue:
$11.02B+$1.15B(+11.66%)Summary
- As of April 2, 2025, VRTX annual revenue is $11.02 billion, with the most recent change of +$1.15 billion (+11.66%) on December 31, 2024.
- During the last 3 years, VRTX annual revenue has risen by +$3.45 billion (+45.49%).
- VRTX annual revenue is now at all-time high.
Performance
VRTX Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Revenue:
$2.91B+$140.10M(+5.05%)Summary
- As of April 2, 2025, VRTX quarterly revenue is $2.91 billion, with the most recent change of +$140.10 million (+5.05%) on December 31, 2024.
- Over the past year, VRTX quarterly revenue has stayed the same.
- VRTX quarterly revenue is now at all-time high.
Performance
VRTX Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM Revenue:
$11.02B+$394.30M(+3.71%)Summary
- As of April 2, 2025, VRTX TTM revenue is $11.02 billion, with the most recent change of +$394.30 million (+3.71%) on December 31, 2024.
- Over the past year, VRTX TTM revenue has stayed the same.
- VRTX TTM revenue is now at all-time high.
Performance
VRTX TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
VRTX Revenue Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +11.7% | 0.0% | 0.0% |
| 3 y3 years | +45.5% | +24.8% | +26.7% |
| 5 y5 years | +164.7% | +24.8% | +26.7% |
VRTX Revenue Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +45.5% | at high | +38.8% | at high | +38.7% |
| 5 y | 5-year | at high | +164.7% | at high | +92.2% | at high | +128.7% |
| alltime | all time | at high | >+9999.0% | at high | +9595.2% | at high | >+9999.0% |
Vertex Pharmaceuticals Incorporated Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $11.02B(+11.7%) | $2.91B(+5.1%) | $11.02B(+3.7%) |
| Sep 2024 | - | $2.77B(+4.8%) | $10.63B(+2.8%) |
| Jun 2024 | - | $2.65B(-1.7%) | $10.34B(+1.5%) |
| Mar 2024 | - | $2.69B(+6.9%) | $10.19B(+3.2%) |
| Dec 2023 | $9.87B(+10.5%) | $2.52B(+1.4%) | $9.87B(+2.2%) |
| Sep 2023 | - | $2.48B(-0.4%) | $9.65B(+1.6%) |
| Jun 2023 | - | $2.49B(+5.0%) | $9.51B(+3.2%) |
| Mar 2023 | - | $2.37B(+3.1%) | $9.21B(+3.1%) |
| Dec 2022 | $8.93B(+17.9%) | $2.30B(-1.4%) | $8.93B(+2.6%) |
| Sep 2022 | - | $2.33B(+6.3%) | $8.70B(+4.2%) |
| Jun 2022 | - | $2.20B(+4.7%) | $8.35B(+5.1%) |
| Mar 2022 | - | $2.10B(+1.2%) | $7.95B(+4.9%) |
| Dec 2021 | $7.57B(+22.1%) | $2.07B(+4.5%) | $7.57B(+6.2%) |
| Sep 2021 | - | $1.98B(+10.6%) | $7.13B(+6.7%) |
| Jun 2021 | - | $1.79B(+4.0%) | $6.68B(+4.2%) |
| Mar 2021 | - | $1.72B(+5.9%) | $6.41B(+3.4%) |
| Dec 2020 | $6.21B(+49.1%) | $1.63B(+5.8%) | $6.21B(+3.6%) |
| Sep 2020 | - | $1.54B(+0.9%) | $5.99B(+10.9%) |
| Jun 2020 | - | $1.52B(+0.6%) | $5.40B(+12.1%) |
| Mar 2020 | - | $1.52B(+7.2%) | $4.82B(+15.8%) |
| Dec 2019 | $4.16B(+36.6%) | $1.41B(+48.8%) | $4.16B(+15.0%) |
| Sep 2019 | - | $949.83M(+0.9%) | $3.62B(+4.8%) |
| Jun 2019 | - | $941.29M(+9.7%) | $3.45B(+5.8%) |
| Mar 2019 | - | $858.43M(-1.3%) | $3.27B(+7.1%) |
| Dec 2018 | $3.05B(+22.5%) | $870.11M(+10.9%) | $3.05B(+7.7%) |
| Sep 2018 | - | $784.53M(+4.3%) | $2.83B(+7.9%) |
| Jun 2018 | - | $752.16M(+17.4%) | $2.62B(+8.6%) |
| Mar 2018 | - | $640.80M(-1.7%) | $2.41B(-3.0%) |
| Dec 2017 | $2.49B(+46.2%) | $651.63M(+12.7%) | $2.49B(+8.4%) |
| Sep 2017 | - | $578.16M(+6.3%) | $2.30B(+7.7%) |
| Jun 2017 | - | $544.13M(-23.9%) | $2.13B(+5.6%) |
| Mar 2017 | - | $714.72M(+55.8%) | $2.02B(+18.6%) |
| Dec 2016 | $1.70B(+64.9%) | $458.71M(+10.9%) | $1.70B(+2.5%) |
| Sep 2016 | - | $413.78M(-4.1%) | $1.66B(+6.7%) |
| Jun 2016 | - | $431.61M(+8.4%) | $1.56B(+20.6%) |
| Mar 2016 | - | $398.08M(-4.8%) | $1.29B(+25.1%) |
| Dec 2015 | $1.03B(+77.9%) | $417.94M(+34.9%) | $1.03B(+36.0%) |
| Sep 2015 | - | $309.82M(+86.6%) | $758.96M(+20.8%) |
| Jun 2015 | - | $166.08M(+19.9%) | $628.13M(+4.6%) |
| Mar 2015 | - | $138.51M(-4.2%) | $600.47M(+3.5%) |
| Dec 2014 | $580.41M(-52.1%) | $144.56M(-19.2%) | $580.41M(-26.3%) |
| Sep 2014 | - | $178.99M(+29.3%) | $787.02M(-5.1%) |
| Jun 2014 | - | $138.42M(+16.9%) | $829.73M(-17.2%) |
| Mar 2014 | - | $118.45M(-66.3%) | $1.00B(-17.3%) |
| Dec 2013 | $1.21B(-20.6%) | $351.16M(+58.4%) | $1.21B(+1.4%) |
| Sep 2013 | - | $221.70M(-28.7%) | $1.19B(-8.7%) |
| Jun 2013 | - | $310.75M(-5.4%) | $1.31B(-7.6%) |
| Mar 2013 | - | $328.37M(-1.7%) | $1.42B(-7.2%) |
| Dec 2012 | $1.53B(+8.3%) | $333.99M(-0.6%) | $1.53B(-13.1%) |
| Sep 2012 | - | $336.01M(-19.7%) | $1.76B(-15.5%) |
| Jun 2012 | - | $418.31M(-4.7%) | $2.08B(+17.1%) |
| Mar 2012 | - | $438.74M(-22.1%) | $1.78B(+25.9%) |
| Dec 2011 | $1.41B(+883.9%) | $563.34M(-14.5%) | $1.41B(+54.5%) |
| Sep 2011 | - | $659.20M(+476.1%) | $912.81M(+229.1%) |
| Jun 2011 | - | $114.42M(+55.3%) | $277.40M(+42.5%) |
| Mar 2011 | - | $73.66M(+12.4%) | $194.60M(+35.7%) |
| Dec 2010 | $143.37M(+40.7%) | $65.52M(+175.4%) | $143.37M(+28.3%) |
| Sep 2010 | - | $23.80M(-24.8%) | $111.73M(-1.0%) |
| Jun 2010 | - | $31.62M(+41.0%) | $112.90M(+12.5%) |
| Mar 2010 | - | $22.43M(-33.8%) | $100.34M(-1.5%) |
| Dec 2009 | $101.89M(-41.9%) | $33.89M(+35.8%) | $101.89M(+1.1%) |
| Sep 2009 | - | $24.96M(+30.9%) | $100.81M(-6.2%) |
| Jun 2009 | - | $19.06M(-20.5%) | $107.46M(-31.9%) |
| Mar 2009 | - | $23.98M(-26.9%) | $157.81M(-10.1%) |
| Dec 2008 | $175.50M(-11.8%) | $32.81M(+3.8%) | $175.50M(-9.4%) |
| Sep 2008 | - | $31.61M(-54.5%) | $193.69M(-4.6%) |
| Jun 2008 | - | $69.41M(+66.5%) | $203.09M(+18.2%) |
| Mar 2008 | - | $41.67M(-18.3%) | $171.88M(-13.6%) |
| Dec 2007 | $199.01M | $50.99M(+24.3%) | $199.01M(-17.9%) |
| Sep 2007 | - | $41.01M(+7.4%) | $242.27M(-4.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2007 | - | $38.20M(-44.5%) | $254.55M(+3.4%) |
| Mar 2007 | - | $68.81M(-27.0%) | $246.08M(+13.7%) |
| Dec 2006 | $216.36M(+34.5%) | $94.25M(+76.9%) | $216.36M(+16.4%) |
| Sep 2006 | - | $53.29M(+79.3%) | $185.86M(+10.1%) |
| Jun 2006 | - | $29.73M(-23.9%) | $168.78M(-1.5%) |
| Mar 2006 | - | $39.09M(-38.7%) | $171.37M(+6.5%) |
| Dec 2005 | $160.89M(+56.6%) | $63.76M(+76.1%) | $160.89M(+17.5%) |
| Sep 2005 | - | $36.21M(+12.0%) | $136.97M(+7.4%) |
| Jun 2005 | - | $32.32M(+13.0%) | $127.59M(+12.1%) |
| Mar 2005 | - | $28.61M(-28.2%) | $113.81M(+10.8%) |
| Dec 2004 | $102.72M(+48.6%) | $39.84M(+48.5%) | $102.72M(+21.9%) |
| Sep 2004 | - | $26.83M(+44.7%) | $84.26M(+15.0%) |
| Jun 2004 | - | $18.54M(+5.9%) | $73.25M(+1.3%) |
| Mar 2004 | - | $17.51M(-18.1%) | $72.29M(-6.6%) |
| Dec 2003 | $69.14M(-27.0%) | $21.38M(+35.1%) | $77.39M(+131.2%) |
| Sep 2003 | - | $15.82M(-10.0%) | $33.48M(-35.5%) |
| Jun 2003 | - | $17.58M(-22.3%) | $51.93M(-32.3%) |
| Mar 2003 | - | $22.61M(-200.3%) | $76.68M(-19.1%) |
| Dec 2002 | $94.77M(+11.1%) | -$22.53M(-165.7%) | $94.77M(+9.4%) |
| Sep 2002 | - | $34.28M(-19.0%) | $86.63M(-6.6%) |
| Jun 2002 | - | $42.33M(+4.0%) | $92.72M(+29.1%) |
| Mar 2002 | - | $40.70M(-232.7%) | $71.84M(+43.1%) |
| Dec 2001 | $85.30M(-44.4%) | -$30.67M(-176.0%) | $50.20M(-71.4%) |
| Sep 2001 | - | $40.37M(+88.3%) | $175.73M(+17.8%) |
| Jun 2001 | - | $21.44M(+12.5%) | $149.22M(-9.5%) |
| Mar 2001 | - | $19.06M(-79.9%) | $164.82M(+7.1%) |
| Dec 2000 | $153.28M(+202.9%) | $94.86M(+584.1%) | $153.89M(+79.1%) |
| Sep 2000 | - | $13.87M(-62.6%) | $85.93M(+8.4%) |
| Jun 2000 | - | $37.03M(+355.4%) | $79.26M(+44.8%) |
| Mar 2000 | - | $8.13M(-69.8%) | $54.74M(+8.2%) |
| Dec 1999 | $50.60M(+73.9%) | $26.90M(+273.6%) | $50.61M(+151.6%) |
| Sep 1999 | - | $7.20M(-42.5%) | $20.12M(-35.8%) |
| Jun 1999 | - | $12.52M(+212.9%) | $31.32M(+20.4%) |
| Mar 1999 | - | $4.00M(-211.1%) | $26.00M(+3.2%) |
| Dec 1998 | $29.10M(-33.6%) | -$3.60M(-119.6%) | $25.20M(-37.0%) |
| Sep 1998 | - | $18.40M(+155.6%) | $40.00M(+14.0%) |
| Jun 1998 | - | $7.20M(+125.0%) | $35.10M(-12.5%) |
| Mar 1998 | - | $3.20M(-71.4%) | $40.10M(-8.4%) |
| Dec 1997 | $43.80M(+135.5%) | $11.20M(-17.0%) | $43.80M(+2.6%) |
| Sep 1997 | - | $13.50M(+10.7%) | $42.70M(+33.0%) |
| Jun 1997 | - | $12.20M(+76.8%) | $32.10M(+39.6%) |
| Mar 1997 | - | $6.90M(-31.7%) | $23.00M(+23.7%) |
| Dec 1996 | $18.60M(-15.8%) | $10.10M(+248.3%) | $18.60M(+11.4%) |
| Sep 1996 | - | $2.90M(-6.5%) | $16.70M(+3.7%) |
| Jun 1996 | - | $3.10M(+24.0%) | $16.10M(-17.4%) |
| Mar 1996 | - | $2.50M(-69.5%) | $19.50M(-11.8%) |
| Dec 1995 | $22.10M(+12.8%) | $8.20M(+256.5%) | $22.10M(+33.1%) |
| Sep 1995 | - | $2.30M(-64.6%) | $16.60M(-20.2%) |
| Jun 1995 | - | $6.50M(+27.5%) | $20.80M(+8.9%) |
| Mar 1995 | - | $5.10M(+88.9%) | $19.10M(-2.6%) |
| Dec 1994 | $19.60M(-29.7%) | $2.70M(-58.5%) | $19.60M(-43.8%) |
| Sep 1994 | - | $6.50M(+35.4%) | $34.90M(+6.4%) |
| Jun 1994 | - | $4.80M(-14.3%) | $32.80M(+0.6%) |
| Mar 1994 | - | $5.60M(-68.9%) | $32.60M(+16.8%) |
| Dec 1993 | $27.90M(+634.2%) | $18.00M(+309.1%) | $27.90M(+156.0%) |
| Sep 1993 | - | $4.40M(-4.3%) | $10.90M(+45.3%) |
| Jun 1993 | - | $4.60M(+411.1%) | $7.50M(+92.3%) |
| Mar 1993 | - | $900.00K(-10.0%) | $3.90M(0.0%) |
| Dec 1992 | $3.80M(+18.8%) | $1.00M(0.0%) | $3.90M(+5.4%) |
| Sep 1992 | - | $1.00M(0.0%) | $3.70M(+5.7%) |
| Jun 1992 | - | $1.00M(+11.1%) | $3.50M(+6.1%) |
| Mar 1992 | - | $900.00K(+12.5%) | $3.30M(+3.1%) |
| Dec 1991 | $3.20M(+39.1%) | $800.00K(0.0%) | $3.20M(+6.7%) |
| Sep 1991 | - | $800.00K(0.0%) | $3.00M(+7.1%) |
| Jun 1991 | - | $800.00K(0.0%) | $2.80M(+7.7%) |
| Mar 1991 | - | $800.00K(+33.3%) | $2.60M(+13.0%) |
| Dec 1990 | $2.30M | $600.00K(0.0%) | $2.30M(+35.3%) |
| Sep 1990 | - | $600.00K(0.0%) | $1.70M(+54.5%) |
| Jun 1990 | - | $600.00K(+20.0%) | $1.10M(+120.0%) |
| Mar 1990 | - | $500.00K | $500.00K |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual revenue?
- What is the all time high annual revenue for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual revenue year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly revenue?
- What is the all time high quarterly revenue for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly revenue year-on-year change?
- What is Vertex Pharmaceuticals Incorporated TTM revenue?
- What is the all time high TTM revenue for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated TTM revenue year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual revenue?
The current annual revenue of VRTX is $11.02B
What is the all time high annual revenue for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual revenue is $11.02B
What is Vertex Pharmaceuticals Incorporated annual revenue year-on-year change?
Over the past year, VRTX annual revenue has changed by +$1.15B (+11.66%)
What is Vertex Pharmaceuticals Incorporated quarterly revenue?
The current quarterly revenue of VRTX is $2.91B
What is the all time high quarterly revenue for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly revenue is $2.91B
What is Vertex Pharmaceuticals Incorporated quarterly revenue year-on-year change?
Over the past year, VRTX quarterly revenue has changed by $0.00 (0.00%)
What is Vertex Pharmaceuticals Incorporated TTM revenue?
The current TTM revenue of VRTX is $11.02B
What is the all time high TTM revenue for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high TTM revenue is $11.02B
What is Vertex Pharmaceuticals Incorporated TTM revenue year-on-year change?
Over the past year, VRTX TTM revenue has changed by $0.00 (0.00%)